sorafenib has been researched along with Acute Disease in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rivington, J; Twohig, P | 1 |
| Bao, XB; Chen, SN; Ding, ZX; He, J; Li, Z; Liu, H; Liu, SB; Qiu, QC; Shen, HJ; Wang, C; Xue, SL; Yang, J; Yao, H | 1 |
| Gabrilove, J; Gong, P; Jing, Y; Li, Y; Wang, R; Waxman, S | 1 |
| Bose, P; Cortes, JE; Dalle, IA; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, HM; Loghavi, S; Naqvi, K; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, N; Yalniz, F; Yilmaz, M | 1 |
| Bellot, P; Llanos, L; Pérez-Mateo, M; Such, J; Zapater, P | 1 |
| Burchert, A; Chaturvedi, A; Eilers, M; Enghofer, E; Metzelder, S; Neubauer, A; Teichler, S; Wang, Y; Wanzel, M; Wollmer, E | 1 |
| Polliack, A; Tadmor, T; Tallman, MS | 1 |
| Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R | 1 |
| Saadati, H; Saif, MW | 1 |
| Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V | 1 |
| Lowe, SW; Pardee, TS; Zuber, J | 1 |
| Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M | 1 |
| Li, M; Srinivas, S | 1 |
1 review(s) available for sorafenib and Acute Disease
| Article | Year |
|---|---|
Sorafenib-Induced Acute Pancreatitis: Case Report and Review of the Literature.
Topics: Acute Disease; Antineoplastic Agents; Humans; Male; Middle Aged; Pancreatitis; Sorafenib | 2019 |
1 trial(s) available for sorafenib and Acute Disease
| Article | Year |
|---|---|
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
11 other study(ies) available for sorafenib and Acute Disease
| Article | Year |
|---|---|
The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
Topics: Acute Disease; Adult; Asian People; China; Drug Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
Arsenic Trioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD Acute Myeloid Leukemia Cells.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Sorafenib; Synthetic Lethal Mutations; Tandem Repeat Sequences; THP-1 Cells; Xenograft Model Antitumor Assays | 2018 |
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Remission Induction; Sorafenib; Staurosporine; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2019 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2009 |
Sorafenib - a small molecule with big promise?
Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fatigue; Humans; Leukemia, Myeloid; Metabolic Clearance Rate; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Sorafenib-induced acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cytarabine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Survival Analysis; Tandem Repeat Sequences; Tumor Suppressor Protein p53 | 2011 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intolerance; Heart Failure; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
Acute pancreatitis associated with sorafenib.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Tomography, X-Ray Computed | 2007 |